Pharmaceutical applications of chitosan in skin regeneration: A review

Skin regeneration is the process that restores damaged tissues. When the body experiences trauma or surgical incisions, the skin and tissues on the wound surface become damaged. The body repairs this damage through complex physiological processes to restore the original structural and functional states of the affected tissues. Chitosan, a degradable natural bioactive polysaccharide, has attracted widespread attention partly owing to its excellent biocompatibility and antimicrobial properties; additionally, a modified form of this compound has been shown to promote skin regeneration. This review evaluates the recent research progress in the application of chitosan to promote skin regeneration. First, we discuss the basic principles of the extraction and preparation processes of chitosan from its source. Subsequently, we describe the functional properties of chitosan and the optimization of these properties through modification. We then focus on the existing chitosan-based biomaterials developed for clinical applications and their corresponding effects on skin regeneration, particularly in cases of diabetic and burn wounds. Finally, we explore the challenges and prospects associated with the use of chitosan in skin regeneration. Overall, this review provides a reference for related research and contributes to the further development of chitosan-based products in cutaneous skin regeneration.

Simultaneous capturing of mixed contaminants from wastewater using novel one-pot chitosan functionalized with EDTA and graphene oxide adsorbent

The emergence of inorganic and organic contaminants has raised great concerns owing to their adverse impact on human health and ecological security. Herein, first time one-pot process was applied for chitosan (CS) functionalization using graphene oxide (GO) and ethylenediaminetetraacetic acid (EDTA) for simultaneous capturing of toxic inorganic (lead (Pb²⁺) and cadmium (Cd²⁺)) and organic (ciprofloxacin (CIP) and sildenafil (SDF)) contaminants from wastewater. In this approach, we believe that CS would work as a backbone, GO would capture both inorganic and organic contaminants via electrostatic interactions, while EDTA would make complexation with heavy metals. Various parameters including pH, reaction time, concentration, reusability etc. were evaluated to achieve the best experimental result in monocomponent system. The prepared adsorbent displayed an excellent monolayer adsorption capacity of 351.20 and 264.10 mg g^-1 for Pb²⁺ and Cd²⁺, respectively, while a heterogeneous sorption capacity of 75.40 and 40.90 mg g^-1 for CIP and SDF, respectively. The kinetics data fitted well to Pseudo-second order (PSO) kinetics model for both types of contaminants and gave faster interaction towards metal ions (higher k₂) than organic contaminants. Experimental results showed excellent adsorption efficiencies at environmental levels in the capturing of both inorganic and organic contaminants at the same time from polluted water. The capturing mechanism of both types of contaminants was explained by elemental mapping, EDS, and FT-IR spectra. Overall, easy synthesis, excellent capturing capacity, and reusability imply that the prepared adsorbent has a sufficient potential for the treatment of co-existing toxic contaminants in water.

Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug

Nanoparticles (NP) only different in mucoadhesivity are compared for impact on drug oral bioavailability. Two polymeric NP types based on quaternary ammonium-chitosan (NP QA-Ch) and S-protected thiolated derivative thereof (NP QA-Ch-S-pro), respectively, containing the macromolecular drug model, FD4, were prepared by crosslinking each polymer with reduced MW hyaluronic acid. The structure of basic polymers was determined by H¹NMR analysis. NP were similar in size (371 ± 38 vs. 376 ± 82 nm); polydispersity index (0.39 ± 0.08 vs. 0.41 ± 0.10); zeta potential (13.4 ± 0.9 vs. 11.9 ± 1.2 mV); reversible interactions with drug (bound drug, 67 vs. 66%); encapsulation efficiency (23 ± 5 vs. 23 ± 8%); release properties (15% released in 15 h in both cases); and apparent permeation across excised rat intestine (P_app, 8.8 ± 0.8 vs. 10 ± 1 cm/s). Then the differences in NP transport ratio through mucus (TR, 0.75 vs. 0.37) and adhesion to excised rat intestinal mucosa (adsorbed fraction, 23 ± 3 vs. 45 ± 2%) were ascribed to higher mucoadhesivity of NP QA-Ch-S-pro compared to NP QA-Ch. This directly influenced drug oral bioavailability in rats (T_max, 1 vs. 2 h; AUC, 1.7 ± 0.3 vs. 2.9 ± 0.4 μg/mL min, for NP QA-Ch and NP QA-Ch-S-pro, respectively). Mucoadhesivity increases drug bioavailability by retaining NP at its absorption site and opposing its transit down the GI tract. Data on drug accumulation in rat liver allows the assertion that NP is absorbed by transcytosis across intestinal epithelium and transported from blood into liver by Kuppfer cells.